Pfizer Archives - InnoHEALTH magazine

Pfizer’s new at-home pill to treat Covid could be available by end of the year

InnoHEALTH magazine digital team — Tue, 22 Jun 2021 05:20:14 +0000

Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who have contracted the virus. Given the way that the virus is mutating and with its impact globally, it looks like that it will be critical to have access to the therapeutic options both now and beyond the pandemic. Hence, Pfizer has initiated phase 1 study of its novel oral antiviral therapeutic agent against Sars-cov-2. On the brighter side, if this proves to be as effective as it claims, it would be a boon to the healthcare system as it would curtail the shortage of the only existing oral drug (Remdesivir) in the market and will act as a potential oral therapy that could be prescribed at the first sign of infection, without requiring the patients to be hospitalized.

Pfizer CEO Albert Bourla has said that an oral drug for treating coronavirus could be ready next year adding the company is working on two antivirals, an oral and an injectable. “We are actually on two, one is injectable and the other one an oral (antiviral). Particularly the attention is on the oral for the world and of us because provides several advantages and one of them is that you don’t need to go to the hospital to get the treatment of which is the case with all the injectables so far but you can get it home,” Bourla told CNBC in an interview on Tuesday, as cited by The Hill.

“If all goes well, and we implement the same speed that we are, and if regulators do the same, and they are, I hope that by the end of the year,” Bourla added.

The only antiviral currently approved for use against the coronavirus is Remdesivir, which is manufactured by Gilead Sciences. The US Food and Drug Administration (FDA) gave the drug full approval in October after it was granted emergency use authorization in May last year. He also said the medication could be “way more effective against the multiple variants” of the virus than current options adding that the mechanism of action, of the antiviral, is not expected to be subject to mutations, “particularly because it’s not acting on the spike, as we all know, all the mutations that we are hearing right now are seeing this in the proteins of the spike.”

“This one doesn’t work there so that allows us to believe that will be way more effective against the multiple variants. So, all good news. We are now progressing the studies and we will have more news around summer,” the CEO added. The Hill further reported that thus far, more than 121 million doses of the vaccine have been administered across the United States.

SOURCE: www.hindustantimes.com

The post Pfizer’s new at-home pill to treat Covid could be available by end of the year appeared first on InnoHEALTH magazine.

Discover Clinical Research in Sweden

InnoHEALTH Magazine — Tue, 15 Oct 2019 08:54:11 +0000

Discover clinical research in region Västra Götaland in Sweden: Home to cross-boundary collaboration and cutting-edge research

In Sweden, six healthcare regions collaborate to facilitate for industry and academia to conduct clinical research. Each region has established a coordinating center offering professional resources. Read about Indo-Swedish Collaboration

The region of Västra Götaland in Sweden is one of the twenty fastest growing European regions. Both traditional industries and new research and technology sectors enjoy a strong position here – not least because of the frequent collaboration between them.

The cooperative environment and prominent clinical research have contributed to the development of life science in the region of Västra Götaland. The region is home to one of Europe’s largest university hospitals (the Sahlgrenska University Hospital) and cutting edge research in biomedicine and the natural sciences, and a strong research based industry. Amongst other researchers, the late Per-Ingvar Brånemark revolutionized modern dentistry with the discovery that titanium could fuse into bone as well as AstraZeneca R&D. Read about The Swedish Solution to a Global Challenge

In region Västra Götaland, Gothia Forum serves as a single point of entry and helps find the appropriate resources to successfully conduct clinical trials in the region. The organisation is part of a large ecosystem including state-of-theart infrastructure andcutting-edge life science research. Gothia Forum aims to strengthen and improve the collaboration between healthcare, academia and industry to strengthen clinical research.

Gothia Forum functions as a meeting point and voluntary resource for everyone working with clinical research in the region and offers services throughout the entire research process such as project management, feasibility, biobanking, legal advice and quality support.

The organisation consists of four units: Research Support Office, the Clinical Trial Center, Primary Care Trial Center and Organisational development, administration and strategic support. Apart from own resources, Gothia Forum has a wide network, and works as a point of contact for those looking for research resources or specialistcompetencies in the region.

Gothia Forum is the result ofa collaboration between the University of Gothenburg, the researchindustry (represented by AstraZeneca, MSD, Pfizer, and Swedish Medtech), Sahlgrenska University Hospital (among other hospitals in the region) and Chalmers Universityof Technology.

About the Author

Dr. Alessio Degl’ Innocenti is an Associate Professor in Psychology and Head of Department at Sahlgrenska University Hospital, Sweden. He is associated with the Gothia Forum for clinical research. He graduated with a Ph.D. in Psychology from the University of Gothenburg in 1998, with a thesis on memory functioning in aging and depression.

The post Discover Clinical Research in Sweden appeared first on InnoHEALTH magazine.

Beactica, BluSense Diagnostics and Optomed announced as winners of the prestigious Nordic Stars 2018 Award at NLSDays in Stockholm

InnoHEALTH Magazine — Thu, 13 Sep 2018 05:23:59 +0000

Stockholm, September 12, 2017. Beactica, BluSense Diagnostics and Optomed are the recipients of the Nordic Stars 2018 Award. The highly coveted award was presented to the winners from three Nordic countries at the conclusion of the Nordic Life Science Days (NLSDays) in Stockholm. Growing numbers of one-on-one meetings and licensing opportunities year by year to a new all-time high underpin that the conference has become an established arena for high quality meetings between, companies, service providers, investors, research communities, and government and regulatory bodies. Approximately 1,280 delegates representing almost 800 companies from 40 countries joined the conference, thus confirming NLSDays’ role as the premier Nordic life sciences event.

Nordic Stars Award were introduced in 2013 in special recognition of life science companies in the Nordic region demonstrating outstanding innovation and entrepreneurial skills.

Björn Ursing, Chairman of the Nordic Stars Award commented:

“At SwedenBIO we are proud to present the three winners of the Nordic Stars Award 2018. Each of them constitutes an excellent example of how companies from the Nordics succeed in developing solutions that can contribute to better healthcare globally.”

This year’s winners are:

Beactica

Beactica has through a series of EU-grants and discovery collaborations with several global pharmaceutical companies proved to be a trusted partner in fragment-based lead generation. They have also used their proprietary methodologies to pursue their own drug discovery programs in oncology, attracting widespread interest from both investors and international pharma companies.

http://www.beactica.com/
BluSense Diagnostics

BluSense Diagnostics has developed an innovative point-of-care platform for accurate, portable and affordable infectious disease diagnostics. With a grant from European Innovation Council pilot (EIC pilot) and CE-marking for their reader and the first diagnostic test for acute dengue fever, they are now on the verge of a market launch, less than four years after incorporation.

https://www.blusense-diagnostics.com/
Optomed

Optomed has made fundus screening readily available and affordable for even small practices. Their devices in combination with AI-based software have enhanced detection of diabetic retinopathy. In addition to having a medical device filling specific needs, they have been successful in commercialization, making it available to patients worldwide.

https://www.optomed.com/

High resolution picture of the winners will be uploaded to My Newsdesk soonest possible after the award ceremony. Scroll down to the bottom, see “Relaterat / Bilder & Videor”.

Jonas Ekstrand, Director General of SwedenBIO also reflected on the highly successful two days:

“Nordic Life Science Days with its unique atmosphere, has once again proved to be the premium conference, partnering and networking event within life science in Northern Europe. Join us next year again when the conference takes place in Malmö in the south of Sweden.”

Nordic Life Science Days 2018 in brief

Companies/Organizations: 780
Registered Delegates: 1280
Meeting requests: 14800
Meeting accepted: 2900
Partnering opportunities: 720

Malmö again next year

NLSDays will return to the south of Sweden in 2019. Join us next year in Malmö on September 10-12.

NLSDays

It is a SwedenBIO event, produced by Bionordic. NLSDays was founded in 2012 and has grown rapidly to become the largest Nordic partnering conference for the global life science industry.

Among the Big Pharma, investors and other major players registered for the meeting so far are AstraZeneca, MSD, Pfizer, Sanofi, SOBI, Boehringer Ingelheim, Roche, Bristol-Mayer Squibb, Bayer, Novo, Johnson & Johnson Innovation, GE Healthcare, DNB, Industrifonden, HealthCap, BioGeneration Ventures, Almi Invest, Gilde Healthcare, Gimv, Lundbeckfonden Ventures, Seventure Partners, IBM and IQVIA

In addition to partnering, NLSDays also offers an exhibition and a seminar program. Speakers include senior representatives from the global life science companies, investors, and academic leaders who will all share their expertise and views for the future.

www.nlsdays.com
About SwedenBIO

SwedenBIO who is the founder and organizer of the Nordic Life Science Days is the Swedish life science industry organization. Our nearly 200 members operate across all sub-sectors from pharmaceutical, biotechnology, medical technology to diagnostics. SwedenBIO serves to the benefit the entire life science industry in Sweden and is a member-driven, private, non-profit organization. The main objective is to improve the conditions for the life science industry for the benefit of industry growth and business development.

www.swedenbio.se

The post Beactica, BluSense Diagnostics and Optomed announced as winners of the prestigious Nordic Stars 2018 Award at NLSDays in Stockholm appeared first on InnoHEALTH magazine.